Plant Name: Vigna radiata
Collective Molecular Activities at 10μM Activity Cutoff
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| GRM5; GRM1; GRM3; GRM2; GRM8; GRM4; | |
| ADORA3; ADRA2B; HCAR2; | |
| TSHR; | |
| GAA; | |
| GLA; TDP1; BLM; ALDH1A1; USP2; BRCA1; | |
| GRIK3; GRIK5; GRIK1; GRIA4; GRIA2; GRIK2; | |
| MAPK1; | |
| NFKB1; | |
| SLC1A1; SLCO1B3; SLCO1B1; | |
| LMNA; MAPT; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
| Cytochrome P450 Enzymes: | CYP2C19; |
|---|
Detailed Information of Human Protein Targets
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Cytochrome P450 family 2 | CYP2C19 | Cytochrome P450 2C19 | P33261 | CHEMBL3622 |
| Enzyme_unclassified | GLA | Alpha-galactosidase A | P06280 | CHEMBL2524 |
| Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
| Enzyme_unclassified | BLM | Bloom syndrome protein | P54132 | CHEMBL1293237 |
| Enzyme_unclassified | ALDH1A1 | Aldehyde dehydrogenase 1A1 | P00352 | CHEMBL3577 |
| Enzyme_unclassified | USP2 | Ubiquitin carboxyl-terminal hydrolase 2 | O75604 | CHEMBL1293227 |
| Enzyme_unclassified | BRCA1 | Breast cancer type 1 susceptibility protein | P38398 | CHEMBL5990 |
| Hydrolase | GAA | Lysosomal alpha-glucosidase | P10253 | CHEMBL2608 |
| Ionotropic glutamate receptor | GRIK3 | Glutamate receptor ionotropic kainate 3 | Q13003 | CHEMBL3684 |
| Ionotropic glutamate receptor | GRIK5 | Glutamate receptor ionotropic kainate 5 | Q16478 | CHEMBL2675 |
| Ionotropic glutamate receptor | GRIK1 | Glutamate receptor ionotropic kainate 1 | P39086 | CHEMBL1918 |
| Ionotropic glutamate receptor | GRIA4 | Glutamate receptor ionotropic, AMPA 4 | P48058 | CHEMBL3190 |
| Ionotropic glutamate receptor | GRIA2 | Glutamate receptor ionotropic, AMPA 2 | P42262 | CHEMBL4016 |
| Ionotropic glutamate receptor | GRIK2 | Glutamate receptor ionotropic kainate 2 | Q13002 | CHEMBL3683 |
| Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
| Protein Kinase | MAPK1 | MAP kinase ERK2 | P28482 | CHEMBL4040 |
| SLC superfamily of solute carriers | SLCO1B1 | Solute carrier organic anion transporter family member 1B1 | Q9Y6L6 | CHEMBL1697668 |
| SLC superfamily of solute carriers | SLC1A1 | Excitatory amino acid transporter 3 | P43005 | CHEMBL2721 |
| SLC superfamily of solute carriers | SLCO1B3 | Solute carrier organic anion transporter family member 1B3 | Q9NPD5 | CHEMBL1743121 |
| Small molecule receptor (family A GPCR) | ADORA3 | Adenosine A3 receptor | P0DMS8 | CHEMBL256 |
| Small molecule receptor (family A GPCR) | ADRA2B | Alpha-2b adrenergic receptor | P18089 | CHEMBL1942 |
| Small molecule receptor (family A GPCR) | HCAR2 | Hydroxycarboxylic acid receptor 2 | Q8TDS4 | CHEMBL3785 |
| Small molecule receptor (family C GPCR) | GRM5 | Metabotropic glutamate receptor 5 | P41594 | CHEMBL3227 |
| Small molecule receptor (family C GPCR) | GRM1 | Metabotropic glutamate receptor 1 | Q13255 | CHEMBL3772 |
| Small molecule receptor (family C GPCR) | GRM3 | Metabotropic glutamate receptor 3 | Q14832 | CHEMBL2888 |
| Small molecule receptor (family C GPCR) | GRM2 | Metabotropic glutamate receptor 2 | Q14416 | CHEMBL5137 |
| Small molecule receptor (family C GPCR) | GRM8 | Metabotropic glutamate receptor 8 | O00222 | CHEMBL3228 |
| Small molecule receptor (family C GPCR) | GRM4 | Metabotropic glutamate receptor 4 | Q14833 | CHEMBL2736 |
| Transcription Factor | NFKB1 | Nuclear factor NF-kappa-B p105 subunit | P19838 | CHEMBL3251 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
| Unclassified | MAPT | Microtubule-associated protein tau | P10636 | CHEMBL1293224 |
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| CC | GO:0044456; synapse part | GO:0042734; presynaptic membrane | 5.248E-14 | 1.428E-10 | GRIK2, GRIK5, GRM1, GRM2, GRM3, GRM4, GRM5, GRM8 |
| MF | GO:0005215; transporter activity | GO:0005234; extracellularly glutamate-gated ion channel activity | 2.732E-13 | 5.948E-10 | GRIA2, GRIA4, GRIK1, GRIK2, GRIK3, GRIK5 |
| BP | GO:0009987; cellular process | GO:0035235; ionotropic glutamate receptor signaling pathway | 2.300E-12 | 2.782E-09 | GRIA2, GRIA4, GRIK1, GRIK2, GRIK3, GRIK5 |
| MF | Unclassified; | GO:0099600; transmembrane receptor activity | 1.089E-11 | 1.031E-08 | ADORA3, ADRA2B, GRIA2, GRIA4, GRIK1, GRIK2, GRIK3, GRIK5, GRM1, GRM2, GRM3, GRM4, GRM5, GRM8, HCAR2, TSHR |
| MF | GO:0005215; transporter activity | GO:0015277; kainate selective glutamate receptor activity | 2.710E-11 | 2.270E-08 | GRIK1, GRIK2, GRIK3, GRIK5 |
| MF | Unclassified; | GO:0004872; receptor activity | 2.708E-10 | 1.594E-07 | ADORA3, ADRA2B, GRIA2, GRIA4, GRIK1, GRIK2, GRIK3, GRIK5, GRM1, GRM2, GRM3, GRM4, GRM5, GRM8, HCAR2, TSHR |
| BP | GO:0023052; signaling | GO:0060079; excitatory postsynaptic potential | 1.142E-09 | 5.781E-07 | GRIA2, GRIA4, GRIK1, GRIK2, GRIK3, GRIK5 |
| CC | GO:0044456; synapse part | GO:0045211; postsynaptic membrane | 3.536E-08 | 1.674E-05 | GRIA2, GRIA4, GRIK1, GRIK2, GRIK3, GRIK5, GRM3 |
| BP | GO:0009987; cellular process | GO:0010646; regulation of cell communication | 4.585E-07 | 1.783E-04 | ADRA2B, BLM, BRCA1, GRIK1, GRIK2, GRIK3, GRIK5, GRM1, GRM2, GRM3, GRM4, GRM5, GRM8, HCAR2, LMNA, MAPK1, MAPT, NFKB1 |
| BP | GO:0023052; signaling | GO:0023051; regulation of signaling | 5.524E-07 | 2.110E-04 | ADRA2B, BLM, BRCA1, GRIK1, GRIK2, GRIK3, GRIK5, GRM1, GRM2, GRM3, GRM4, GRM5, GRM8, HCAR2, LMNA, MAPK1, MAPT, NFKB1 |
| MF | GO:0060089; molecular transducer activity | GO:0001641; group II metabotropic glutamate receptor activity | 2.493E-06 | 8.755E-04 | GRM2, GRM3 |
| CC | GO:0044464; cell part | GO:0032838; plasma membrane bounded cell projection cytoplasm | 3.876E-06 | 1.260E-03 | GRIK2, GRIK3, MAPK1, MAPT |
| BP | Unclassified; | GO:0099566; regulation of postsynaptic cytosolic calcium ion concentration | 7.471E-06 | 2.226E-03 | GRM1, GRM5 |
| BP | GO:0008152; metabolic process | GO:0019220; regulation of phosphate metabolic process | 7.666E-06 | 2.226E-03 | ADRA2B, BLM, GRIK2, GRM1, GRM2, GRM3, GRM4, GRM5, GRM8, MAPK1, MAPT, TSHR |
| MF | GO:0060089; molecular transducer activity | GO:0099583; neurotransmitter receptor activity involved in regulation of postsynaptic cytosolic calcium ion concentration | 7.471E-06 | 2.226E-03 | GRM1, GRM5 |
| CC | GO:0032991; macromolecular complex | GO:0032983; kainate selective glutamate receptor complex | 7.471E-06 | 2.226E-03 | GRIK2, GRIK5 |
| CC | GO:0044464; cell part | GO:0032839; dendrite cytoplasm | 8.405E-06 | 2.346E-03 | GRIK2, GRIK3, MAPK1 |
| MF | GO:0005215; transporter activity | GO:0008381; mechanosensitive ion channel activity | 1.284E-05 | 3.369E-03 | GRIA2, GRIA4, GRIK1, GRIK2, GRIK3, GRIK5 |
| BP | GO:0032501; multicellular organismal process | GO:0044057; regulation of system process | 1.458E-05 | 3.684E-03 | ADORA3, ADRA2B, GAA, GRM1, HCAR2, LMNA, SLC1A1 |
| CC | GO:0043226; organelle | GO:0014069; postsynaptic density | 1.472E-05 | 3.684E-03 | GRIK2, GRIK5, GRM1, GRM3, GRM5 |
| MF | GO:0005215; transporter activity | GO:0004971; AMPA glutamate receptor activity | 1.493E-05 | 3.693E-03 | GRIA2, GRIA4 |
| BP | GO:0051179; localization | GO:0006811; ion transport | 2.302E-05 | 5.448E-03 | GRIA2, GRIA4, GRIK1, GRIK2, GRIK3, GRIK5, GRM2, SLC1A1, SLCO1B1, SLCO1B3 |
| MF | GO:0005215; transporter activity | GO:0098782; mechanosensitived potassium channel activity | 3.202E-05 | 7.262E-03 | GRIK1, GRIK2, GRIK3, GRIK5 |
| CC | GO:0044464; cell part | GO:0043204; perikaryon | 3.313E-05 | 7.438E-03 | GRIK2, GRIK3, GRIK5, MAPK1 |
| BP | GO:0050896; response to stimulus | GO:0071417; cellular response to organonitrogen compound | 3.362E-05 | 7.469E-03 | BLM, BRCA1, GRM5, MAPK1, NFKB1, TSHR |
| BP | GO:0008152; metabolic process | GO:0030818; negative regulation of cAMP biosynthetic process | 4.741E-05 | 9.926E-03 | GRM2, GRM3, GRM8 |
| BP | GO:0009987; cellular process | GO:0007196; adenylate cyclase-inhibiting G-protein coupled glutamate receptor signaling pathway | 4.750E-19 | 3.448E-15 | GRIK3, GRM1, GRM2, GRM3, GRM4, GRM5, GRM8 |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10, ordered by adjusted p-value
Detailed Information of Enriched KEGG Pathways
| Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|
| hsa04724 | Glutamatergic synapse_Homo sapiens_hsa04724 | 4.092E-24 | 5.525E-22 | GRIA2; GRIK5; SLC1A1; GRIK3; GRIK1; GRIK2; GRM1; GRM3; GRM2; GRM5; GRM4; GRM8; MAPK1; GRIA4 |
| hsa04080 | Neuroactive ligand-receptor interaction_Homo sapiens_hsa04080 | 2.231E-20 | 1.506E-18 | GRIA2; GRIK5; GRIK3; GRIK1; GRIK2; ADRA2B; TSHR; GRM1; GRM3; GRM2; GRM5; GRM4; ADORA3; GRM8; GRIA4 |
| hsa04072 | Phospholipase D signaling pathway_Homo sapiens_hsa04072 | 1.971E-09 | 8.870E-08 | GRM3; GRM2; GRM5; GRM4; GRM8; MAPK1; GRM1 |
| hsa04723 | Retrograde endocannabinoid signaling_Homo sapiens_hsa04723 | 4.550E-07 | 1.454E-05 | GRIA2; GRM5; MAPK1; GRM1; GRIA4 |
| hsa04024 | cAMP signaling pathway_Homo sapiens_hsa04024 | 5.385E-07 | 1.454E-05 | HCAR2; GRIA2; MAPK1; NFKB1; TSHR; GRIA4 |
| hsa05030 | Cocaine addiction_Homo sapiens_hsa05030 | 9.528E-07 | 2.144E-05 | GRM3; GRIA2; GRM2; NFKB1 |
| hsa04720 | Long-term potentiation_Homo sapiens_hsa04720 | 3.182E-06 | 6.137E-05 | GRIA2; GRM5; MAPK1; GRM1 |
| hsa04730 | Long-term depression_Homo sapiens_hsa04730 | 1.087E-04 | 1.834E-03 | GRIA2; MAPK1; GRM1 |
| hsa04713 | Circadian entrainment_Homo sapiens_hsa04713 | 4.238E-04 | 5.721E-03 | GRIA2; MAPK1; GRIA4 |
| hsa04540 | Gap junction_Homo sapiens_hsa04540 | 3.384E-04 | 5.076E-03 | GRM5; MAPK1; GRM1 |
| hsa04210 | Apoptosis_Homo sapiens_hsa04210 | 1.307E-03 | 1.357E-02 | LMNA; MAPK1; NFKB1 |
| hsa04071 | Sphingolipid signaling pathway_Homo sapiens_hsa04071 | 8.376E-04 | 1.028E-02 | ADORA3; MAPK1; NFKB1 |
| hsa04022 | cGMP-PKG signaling pathway_Homo sapiens_hsa04022 | 2.165E-03 | 1.948E-02 | ADORA3; MAPK1; ADRA2B |
| hsa05221 | Acute myeloid leukemia_Homo sapiens_hsa05221 | 3.519E-03 | 2.639E-02 | MAPK1; NFKB1 |
| hsa05033 | Nicotine addiction_Homo sapiens_hsa05033 | 1.748E-03 | 1.686E-02 | GRIA2; GRIA4 |
| hsa00052 | Galactose metabolism_Homo sapiens_hsa00052 | 9.844E-04 | 1.107E-02 | GAA; GLA |
| hsa05212 | Pancreatic cancer_Homo sapiens_hsa05212 | 4.689E-03 | 2.963E-02 | MAPK1; NFKB1 |
| hsa05031 | Amphetamine addiction_Homo sapiens_hsa05031 | 4.828E-03 | 2.963E-02 | GRIA2; GRIA4 |
| hsa03460 | Fanconi anemia pathway_Homo sapiens_hsa03460 | 3.050E-03 | 2.574E-02 | BLM; BRCA1 |
| hsa04010 | MAPK signaling pathway_Homo sapiens_hsa04010 | 7.074E-03 | 3.407E-02 | MAPK1; MAPT; NFKB1 |
| hsa04621 | NOD-like receptor signaling pathway_Homo sapiens_hsa04621 | 3.519E-03 | 2.639E-02 | MAPK1; NFKB1 |
| hsa04917 | Prolactin signaling pathway_Homo sapiens_hsa04917 | 5.555E-03 | 2.963E-02 | MAPK1; NFKB1 |
| hsa05220 | Chronic myeloid leukemia_Homo sapiens_hsa05220 | 5.706E-03 | 2.963E-02 | MAPK1; NFKB1 |
| hsa04662 | B cell receptor signaling pathway_Homo sapiens_hsa04662 | 5.706E-03 | 2.963E-02 | MAPK1; NFKB1 |
| hsa05131 | Shigellosis_Homo sapiens_hsa05131 | 4.551E-03 | 2.963E-02 | MAPK1; NFKB1 |
| hsa05140 | Leishmaniasis_Homo sapiens_hsa05140 | 5.706E-03 | 2.963E-02 | MAPK1; NFKB1 |
| hsa04976 | Bile secretion_Homo sapiens_hsa04976 | 5.406E-03 | 2.963E-02 | SLCO1B1; SLCO1B3 |
| hsa04742 | Taste transduction_Homo sapiens_hsa04742 | 7.318E-03 | 3.407E-02 | GRM4; GRM1 |
| hsa04933 | AGE-RAGE signaling pathway in diabetic complications_Homo sapiens_hsa04933 | 1.067E-02 | 4.119E-02 | MAPK1; NFKB1 |
| hsa05215 | Prostate cancer_Homo sapiens_hsa05215 | 8.373E-03 | 3.646E-02 | MAPK1; NFKB1 |
| hsa05206 | MicroRNAs in cancer_Homo sapiens_hsa05206 | 1.072E-02 | 4.119E-02 | MAPK1; BRCA1; NFKB1 |
| hsa04915 | Estrogen signaling pathway_Homo sapiens_hsa04915 | 1.027E-02 | 4.119E-02 | MAPK1; GRM1 |
| hsa05133 | Pertussis_Homo sapiens_hsa05133 | 6.014E-03 | 3.007E-02 | MAPK1; NFKB1 |
| hsa04066 | HIF-1 signaling pathway_Homo sapiens_hsa04066 | 1.108E-02 | 4.119E-02 | MAPK1; NFKB1 |
| hsa05132 | Salmonella infection_Homo sapiens_hsa05132 | 7.837E-03 | 3.527E-02 | MAPK1; NFKB1 |
| hsa04660 | T cell receptor signaling pathway_Homo sapiens_hsa04660 | 1.129E-02 | 4.119E-02 | MAPK1; NFKB1 |
| hsa04151 | PI3K-Akt signaling pathway_Homo sapiens_hsa04151 | 1.552E-02 | 4.764E-02 | MAPK1; BRCA1; NFKB1 |
| hsa04620 | Toll-like receptor signaling pathway_Homo sapiens_hsa04620 | 1.171E-02 | 4.159E-02 | MAPK1; NFKB1 |
| hsa04668 | TNF signaling pathway_Homo sapiens_hsa04668 | 1.256E-02 | 4.349E-02 | MAPK1; NFKB1 |
| hsa05142 | Chagas disease (American trypanosomiasis)_Homo sapiens_hsa05142 | 1.129E-02 | 4.119E-02 | MAPK1; NFKB1 |
| hsa04726 | Serotonergic synapse_Homo sapiens_hsa04726 | 1.300E-02 | 4.388E-02 | MAPK1; CYP2C19 |
| hsa05145 | Toxoplasmosis_Homo sapiens_hsa05145 | 1.435E-02 | 4.727E-02 | MAPK1; NFKB1 |
| hsa04722 | Neurotrophin signaling pathway_Homo sapiens_hsa04722 | 1.482E-02 | 4.763E-02 | MAPK1; NFKB1 |
| hsa04142 | Lysosome_Homo sapiens_hsa04142 | 1.553E-02 | 4.764E-02 | GAA; GLA |
Human Diseases Associated with the Target Proteins of the Plant (Activity≤10μM)
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
|---|---|---|---|
| G00-G99: Diseases of the nervous system G00-G99 | Chronic neuropathic pain | G64, G90.0, K21, R52, G89 | GRM5; GRM5 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Pompe's disease | E74.02 | GAA |
| C00-D49: Neoplasms | Thyroid cancer | C73 | TSHR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Fabry's disease | E75.2 | GLA |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychiatric disorder | F01-F99 | GRM2 |
| G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | GRM2; GRM5; MAPT |
| I00-I99: Diseases of the circulatory system | Cerebrovascular ischaemia | I61-I63 | ADORA3 |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | GRIK1; GRM1; GRM4; GRM5 |
| I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | HCAR2 |
| C00-D49: Neoplasms | Cancer | C00-C96 | ADORA3; MAPK1; NFKB1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Huntington's disease | F02.2, G10 | GRM1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Autism | F84.0 | GRM5 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Schizophrenia | F20 | GRM1; GRM3; GRM2 |
| G00-G99: Diseases of the nervous system G00-G99 | Migraine | G43 | GRM5 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Bipolar disorder | F31, F40-F42 | GRM2 |
| NA: NA | GERD | NA | GRM5 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | GRM3; GRM2; GRM4; GRM5 |
| A00-B99: Certain infectious and parasitic diseases | Malaria | B54 | ADORA3 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Alcohol use disorders | F10.2 | GRIK1; ADRA2B |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | GRM1; GRM3; GRM2; GRM5; MAPT |
| C00-D49: Neoplasms | Hepatocellular carcinoma | C22.0 | ADORA3 |
| NA: NA | Hepatitis C virus infection | NA | ADORA3 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Fragile X syndrome | F02.3, G20, Q99.2 | GRM5 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mood disorder | F30-F39 | GRM2; GRM5 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | HCAR2 |
| G00-G99: Diseases of the nervous system G00-G99 | Epilepsy | G40 | GRIK1; GRIK1 |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | ADORA3 |
| I00-I99: Diseases of the circulatory system | Acute ischemic stroke | I61-I63 | HCAR2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | NFKB1; HCAR2 |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR |
| I00-I99: Diseases of the circulatory system | Ischemia | I99.8 | ADORA3 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depressive disorder | F32, F33, M32 | GRM3; GRM2; GRM2; GRM5; GRM5; HCAR2 |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | MAPK1 |
| I00-I99: Diseases of the circulatory system | Atherosclerosis | I70 | HCAR2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Inflammation | E08-E13, E10.2, E11, E11.2, E13.2, I73.9, I80-I82, N00-N29, G89 | ADORA3 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | MAPT |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | GRIA4; GRIA2 |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | GRIK1; GRM1 |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | MAPT |
| G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | GRIK1; GRM1; GRM5; ADRA2B |
| I00-I99: Diseases of the circulatory system | Arteriosclerosis | I70 | HCAR2 |
| I00-I99: Diseases of the circulatory system | Restenosis | I51.89 | MAPK1 |
| C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR |